Replimune Group Inc is a biotechnology company focused on developing innovative therapies for cancer treatment using its proprietary oncolytic virus platform. By harnessing genetically engineered viruses that selectively target and destroy cancer cells while stimulating the body’s immune system, Replimune aims to revolutionize the approach to cancer care. The company's research and development efforts are centered on creating novel therapeutic options that can potentially provide more effective and less toxic alternatives to traditional cancer treatments. Through their commitment to scientific advancement, Replimune is poised to make significant contributions to the field of oncology. Read More
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK - July 31, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Investor Action Alert – Undercard Stocks Breaking Out Beneath the Surface of the Mag 7 - While Big Tech’s “Mag 7” continues to dominate headlines, a new wave of high-upside small- and mid-cap stocks is making serious noise—and the time to pay attention is now .
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
